HomeMy WebLinkAboutR-2023-081 Resolution authorizing the Memorandum of Understanding between the Greater Columbia Region municipalities to establish an opioid abatement councilRESOLUTION NO. R-2023-081
A RESOLUTION approving the Memorandum of Understanding between the Greater
Columbia Region municipalities to establish an opioid abatement council.
WHEREAS, the City approved the One Washington Memorandum of Understanding
Between Washington Municipalities on April 19, 2022, in which the City agreed to settle any claims
it might have against certain pharmaceutical supply chain entities in exchange for a percentage
of the total negotiated settlement amounts; and
WHEREAS, the City agreed to negotiated settlement amounts with respect to claims
against McKesson, AmerisourceBergen and Cardinal Health, as part of the One Washington
collective group, in September of 2022; and
WHEREAS, the City approved the settlements with pharmacies and manufacturers: Teva,
Allergan, CVS, Walgreens and Walmart; and
WHEREAS, a requirement of the settlement is to establish a regional council to oversee
the use of the settlement funds by each participating jurisdiction; and
WHEREAS, the City Council finds that it is in the best interest of the City of Yakima and
its residents to enter into the Memorandum of Understanding between the Greater Columbia
Region municipalities to establish an opioid abatement council to fulfill the requirement to
establish a regional council for oversight; now, therefore
BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF YAKIMA:
The City Council of the City of Yakima hereby authorizes the City Manager to sign the
Memorandum of Understanding between the Greater Columbia Region municipalities to establish
an opioid abatement council.
ADOPTED BY THE CITY COUNCIL this 6th day of June, 2023.
ATTEST:
\KlMA
• Rosalinda Ibarra, City Clem
Janice Deccio, Mayor
MEMORANDUM OF UNDERSTANDING BETWEEN THE GREATER COLUMBIA
REGION MUNICIPALITIES TO ESTABLISH AN OPIOID ABATEMENT COUNCIL
Whereas, the people of the State of Washington and its communities have been harmed by entities
within the Pharmaceutical Supply Chain who manufacture, distribute, and dispense prescription opioids;
Whereas, certain Local Governments, through their elected representatives and counsel are engaged in
litigation seeking to hold these entities within the Pharmaceutical Supply Chain of prescription opioids
accountable for the damage they have caused to the Local Governments;
Whereas, Local Governments and elected officials share a common desire to abate and alleviate the
impacts of harms caused by these entities within the Pharmaceutical Supply Chain throughout the State
of Washington, and strive to ensure that principals of equity and equitable service delivery are factors
considered in the allocation and use of Opioid Funds;
Whereas, Certain Local Governments engaged in litigation and the other cities and counties in
Washington desire to agree on a form of allocation for Opioid Funds they receive from entities within
the Pharmaceutical Supply Chain;
Whereas, Local Governments who receive funds that are governed by the August 2022 One Washington
Memorandum of Understanding are required to participate in an Opioid Abatement Council to oversee
and approve the plans for the spending of those funds;
Now therefore, the Local Governments within the Greater Columbia Region enter into this
Memorandum of Understanding ("MOU") relating to the formation of an Opioid Abatement Council.
A. Definitions
As used in this MOU:
1. "Administering Agency" shall mean the Greater Columbia Behavioral Health, LLC.
2. "Approved Purposes" shall mean the strategies specified and set forth in the
Opioid Abatement Strategies attached as Exhibit A.
3. "Greater Columbia Region" shall mean the allocation region as determined by the
August 2022 One Washington Memorandum of Understanding between
Washington Municipalities (One Washington MOU) made up of the following
counties: Asotin, Benton, Columbia, Franklin, Garfield, Kittitas, Walla Walla,
Whitman, and Yakima.
4. "Participating Local Governments" shall mean those local governments that have
chosen to sign on to the One Washington MOU. The Participating Local
Governments for this MOU are: Asotin County, Benton County, Columbia County,
Franklin County, Garfield County, Kittitas County, Walla Walla County, Whitman
County, Yakima County, Kennewick, Richland, West Richland, Pasco, Ellensburg,
Walla Walla, Pullman, Grandview, Sunnyside and Yakima.
5. "Opioid Abatement Council (OAC)" shall mean the group of representatives from
the municipalities receiving funds within the Greater Columbia Region to oversee
Opioid fund allocation, distribution, expenditures and dispute resolution as well as
other responsibilities laid out inthis K8OU. See also One Washington MOU.
6 "Opioid Funds" shall mean monetary amounts obtained through a Settlement as
defined inthe One Washington MOU.
B. Oplold Abatement Council
a. All Participating Local Governments may have one representative onthe OAC
subject tothe requirements detailed in the One Washington MC]U.
b. The OACshall meet onaquarterly basis orasneeded, asdetermined bythe
Administering Agency.
c. All Participating Local Governments will submit a spending plan to the OAC that
complies with the Approved Purposes as outlined in Exhibit A, prior to the
Participating Local Governments' expenditure ofany Opinidfunds.
d. Responsibilities ofthe OAC:
i Overseeing distribution ofOpioidFunds from Participating Local
Governments toprograms and services within the Allocation Region for
Approved Purposes.
ii Annual review mfexpenditure reports from Participating Local
Jurisdictions within the Allocation Region for compliance with Approved
Purposes and the terms ofthis K8OUand any Settlement. Tofacilitate this
process, each Participating Local Government shall submit monthly
expenditure reports for each month that funds were distributed.
iii Reporting and making publicly available all decisions on(]pioidFund
allocation applications, distributions and expenditures bythe OACmr
directly bvParticipating Local Governments.
iv. Developing and maintaining a centralized public dashboard or other
repository for the publication ofexpenditure data from any Participating
Local Government that receives Opioid Funds, and for expenditures by the
OACinthat Allocation Region, which itshall update atleast annually.
v. Hearing complaints byParticipating Local Governments within the
Allocation Region regarding alleged failure to:
1. Use Opioid Funds for Approved Purposes or
J. Comply with reporting requirements.
vi. If necessary, requiring and collecting additional outcome related data
from Participating Local Governments toevaluate the use ofOpioid
Funds, and all Participating Local Governments shall comply with such
requirements.
e. If the OAC concludes that a Participating Local Government's expenditure of its
allocation of Opioid Funds did not comply with the Approved Purposes listed in
Exhibit A or the terms of this MOU, or that the Participating Local Government
otherwise misused its allocation of Opioid Funds, the OAC may take remedial
action against the alleged offending Participating Local Government. Such
remedial action is left to the discretion of the OAC and may include withholding
future Opioid Funds owed to the offending Participating Local Government or
requiring the offending Participating Local Government toreimburse improperly
expended Opioid Funds back to the OAC to be re -allocated to the remaining
Participating Local Governments within the Region.
f. All Participating Local Governments and the OAC shall maintain all records related
to the receipt and expenditure of Opioid Funds for no less than five (5) years and
shall make such records available for review by any other Participating Local
Government or OAC, or the public. Records requested by the public shall be
produced in accordance with Washington's Public Records Act RCW 42.56.001 et
seq. Records requested by another Participating Local Government or an OAC
shall be produced within twenty-one (21) days of the date the record request was
received. This requirement does not supplant any Participating Local Government
or OAC's obligations under Washington s Public Records Act RCW 42.56.001 et
seq.
g. Each Participating Local Government may elect to have its share re -allocated to
the OAC. The OAC will then utilize this share for the benefit of Participating Local
Governments within the Allocation Region, consistent with the Approved
Purposes set forth in Exhibit A. A Participating Local Government's election to
forego its allocation of Opioid Funds shall apply to all future allocations unless the
Participating Local Government notifies the OAC otherwise. If a Participating Local
Government elects to forego its allocation of the Opioid Funds, the Participating
Local Government shall be excused from the reporting requirements set forth in
this Agreement.
i. In the case where Participating Local Governments chose to forego their
allocation of Opioid fund, the OAC shall be responsible for:
1. Approving or denying proposals by Participating Local
Governments or community groups to the OAC for use of Opioid
Funds within the Allocation Region.
2. Directing the Trustee to distribute Opioid Funds for use by
Participating Local Governments or community groups whose
proposals are approved by the OAC.
3. Administrating and maintaining records of all OAC decisions and
distributions of Opioid Funds.
h. Participating Local Governments will reserve 10% of the Opioid Funds received for
administrative costs related to the OAC. The OAC will provide an annual
accounting for actual costs, and any remaining funds may then be used for the
Participating Local Government's Approved purpose. The Administering Agency
will be responsible for providing staffing and administrative support for the OAC.
MEMORANDUM OF UNDERSTANDING BETWEEN THE GREATER COLUMBIA
REGION MUNICIPALITIES TO ESTABLISH AN OPIOID ABATEMENT COUNCIL
This Memorandum of Understanding between the Greater Columbia Region Municipalities to Establish
an Opioid Abatement Council is signed this 1 day of 2023 by:
Name & Title
On Behalf of
CITY CONTRACT is
RESOLUTION NO
Exhibit A
OPIOID ABATEMENT STRATEGIES
Participating Local Governments that receive a direct payment maintain full
discretion over the use and distribution of their allocation of Opioid Funds,
provided the Opioid Funds are used solely for Approved Purposes. Reasonable
administrative costs for a Participating Local Government to administer its
allocation of Opioid Funds shall not exceed actual costs or 10% of the
Participating Local Government's allocation Opioid Funds, whichever is less.
PART ONE: TREATMENT
A. TREAT OPIOID USE DISORDER (OUD)
Support treatment of Opioid Use Disorder (OUD) and any co-occurring Substance Use
Disorder or Mental Health (SUD/MH) conditions. Co -usage, and/or co -addiction through
evidence -based, evidence -informed, or promising programs or strategies that may include,
but are not limited to, the following:
1. Expand availability of treatment for OUD and any co-occurring SUD/MH conditions,
co -usage, and/or co -addiction. Including all forms of Medication -Assisted Treatment
(MAT) approved by the U.S. Food and Drug Administration.
2. Support and reimburse services that include the full American Society of Addiction
Medicine (ASAM) continuum of care for OUD and any co-occurring SUD/MH
conditions, co -usage, and/or co -addiction, including but not limited to:
a. Medication -Assisted Treatment (MAT);
b. Abstinence -based treatment;
c. Treatment, recovery, or other services provided by states, subdivisions,
community health centers; non -for -profit providers; or for -profit providers;
d. Treatment by providers that focus mnOUDtreatment aswell astreatment by
providers that offer OUDtreatment along with treatment for other SUD/MH
condition, co -usage, and/or co -addiction; or
e. Evidence- informed residential services programs, as noted below.
3. Expand te|eheabh to increase access totreatment for OUD and any co-occurring
SUD/K4H conditions, co -usage, and/or co -addiction, including MAT, as well as
counseling, psychiatric support, and other treatment and recovery support services.
4. Improve oversight ofOpipid Treatment Programs (OTPs) to assure evidence -based,
evidence -informed, or promising practices such as adequate methadone dosing.
5. Support mobile intervention, treatment, and recovery services, offered by qualified
professional and service providers, such as peer recovery coaches, for persons with
C)UDand any co-occurring SUD/KUHconditions, cm'usage,and/or co -addiction and for
persons who have experienced anopioidoverdose.
6. Support treatment of mental health trauma resulting from the traumatic experiences
of the opioid user (e.g., violence, sexual assault, human trafficking, or adverse
childhood experiences) and family members (e.g., surviving family members after an
overdose or overdose fatality), and training of health care personnel to identify and
address such trauma.
7. Support cletoxification (detox) and withdrawal management services for persons with
OUD and any co-occurring SUD/KAH conditions, cm -usage, and/or co -addiction,
including medical datoo, referral to treatment, mrconnections tm other services or
supports.
8. Support training on MAT for health care providers, students, orother supporting
professionals, such as peer recovery coaches or recovery outreach specialists,
including te|ennentmringtm assist community -based providers in rural or underserved
areas.
9. Support workforce development for addiction professionals who work with persons
with C)UDand any co-occurring SUD/K4Hconditions, co'usage,and/or co-addictimn.
10. Provide fellowships for addiction medicine specialists for direct patient care,
instructors, and clinical research for treatments.
11. Provide funding and training for clinicians tm obtain a waiver under the federal Drug
Addiction Treatment Act of 2000 (DATA 2000) to prescribe MAT for OUD, and provide
technical assistance and professional support tmclinicians who have obtained aDATA
2000xvaiver.
l2.Support the dissemination of web -based training curricula, such as the American
Academy of Addiction Psychiatry's Provider Clinical Support Service-Opioids web -
based training curriculum and motivational interviewing.
13. Support the development and dissemination of new curricula, such as the American
Academy of Addiction Psychiatry's Provider Clinical Support Service for Medication -
Assisted Treatment.
B. SUPPORT PEOPLE IN TREATMENT AND RECOVERY
Support people in treatment for and recovery form OUD and any co-occurring SUD/MH
conditions, co -usage, and/or co -addiction through evidenced -based, evidence -informed, or
promising programs or strategies that may include, but are not limited to, the following:
1. Provide the full continuum of care of recovery services for OUD and any co0occurrinf
SUD/MH condition, co -usage, and/or co -addiction, including supportive housing,
residential treatment, medical detox services, peer support services and counseling,
community navigators, case management, and connections to community -based
services.
2. Provide counseling, peer -support, recovery case management and residential
treatment with access to medications for those who need it to persons with OUD and
any co-occurring SUD/MH conditions, co -usage, and/or co -addiction.
3. Provide access to housing for people with OUD and any co-occurring SUD/MH
conditions, co -usage, and/or co -addiction, including supportive housing, recovery
housing, housing assistance programs, or training for housing providers.
4. Provide community support services. Including social and legal services, to assist in
deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions, co -
usage, and/or co -addiction.
5. Support or expand peer -recovery centers, which may include support groups, social
events, computer access, or other services for persons with OUD and any co-occurring
SUD/MH conditions, co -usage, and/or co -addiction.
6. Provide employment training or educational services for persons in treatment for or
recovery form OUD and any co-occurring SUD/MH conditions, co -usage, and/or co -
addiction.
7. Identify successful recovery programs such as physician, pilot, and college recovery
programs, and provide support and technical assistance to increase the number and
capacity of high -quality programs to help those in recovery.
8. Engage non -profits, faith -based communities, and community coalitions to support
people in treatment and recovery and to support family members in their efforts to
manage the opioid user in the family.
9. Provide training and development of procedures for government staff to
appropriately interact and provide social and other services to current and recovering
opioid users, including reducing stigma.
10. Support stigma reduction efforts regarding treatment and support for persons with
OUD, including reducing the stigma on effective treatment.
C. CONNECT PEOPLE WHO NEED HELP TO THE
Provide connections to care for people who have — or are at risk of developing — OUD and any
co-occurring SUD/K8H conditions, co -usage, and/or co -addiction through evidence -based,
evidence-infmrnmed,orpromising programs prstrategies that may include, but are not limited
to, the following:
l. Ensure that health care providers are screening for OUD and other risk factors and
know how to appropriately counsel and treat (or refer if necessary) a patient for OUD
treatment.
2. Support Screening, Brief Intervention and Referral to Treatment (S0|RT) programs to
reduce the transition from use to disorders.
8. Provide training and long-term implementation of SB|RT in key systems (health,
schools, colleges, criminal justice, and probation), with afocus onyouth and young
adults when transition from misuse toopioid disorder iscommon.
4. Purchase automated versions of SBIRT and support ongoing costs of the technology.
5. Support training for emergency room personnel treating opioid overdose patients on
post -discharge planning, including community referrals for MAT, recovery case
management orsupport services.
O. Support hospital programs that transition persons with <]UD and any co-occurring
SUD/MH conditions, co -usage, and/or co -addiction, or person who have experienced
an mpimid overdose, into community treatment or recovery services through a bridge
clinic mrsimilar approach.
7. Support crisis stabilization centers that serve as an alternative to hospital emergency
departments for persons with OUD and any co-occurring SUD/K8H conditions,
co=usage, and /or co -addiction or persons that have experienced an opioid overdose.
8. Support the work of Emergency Medical Systems, including peer support specialists,
to connect individuals totreatment or other appropriate services following an opimid
overdose orother opioid=re|atedadverse event.
9. Provide funding for peer support specialists or recovery coaches in emergency
departments, detpxtaci|ities, recovery centers, recovery housing, orsimilar settings;
offer services, supports, orconnections tm care to persons with OUD and any co-
occurring SUD/MH conditions, co -usage, and/or co -addiction or to persons who have
experienced anopigidoverdose.
10.Provide funding for peer navigators, recovery coaches, care coordinators, or care
managers that offer assistance to parsons with OUO and any co-occurring SUD/yNH
conditions, cm -usage, and/or co -addiction or to person who have experienced on
mpimidmvendose.
11.Create or support school -based contacts that parents can engage with to seek
immediate treatment services for their child; and support prevention, intervention,
treatment, and recovery programs focused onyoung people.
12. Develop and support best practices on addressing OUD in the workplace.
l3.Support assistance programs for health care providers with OUD.
14. Engage non -profits and the faith community as a system to support outreach for
treatment.
15. Support centralized call centers that provide information and connections to
appropriate services and supports for person s with OUD and any co-occurring
SUD/MH conditions, co -usage, an/or co -addiction.
16. Create or support intake and call centers to facilitate education and access to
treatment, prevention, and recovery services for persons with OUD and any co-
occurring SUD/MH condition, co -usage, and/or co -addiction.
17. Develop or support a National Treatment Availability Clearing house — a
multistate/nationally accessible database whereby health care providers can list
locations for currently available in -patient and out -patient OUD treatment services
that are accessible on a real-time basis by persons who seek treatment.
D. ADDRESS THE NEEDS OF CRIMINAL -JUSTICE -INVOLVED PERSONS
Address the needs of persons with OUD and any co-occurring SUD/MH conditions, co -usage,
and/or co -addiction who are involved — or are at risk of becoming involved — in the criminal
justice system through evidence -based, evidence -informed, or promising programs or
strategies that may include, but are not limited to, the following:
1. Support pre -arrest or post -arrest diversion and deflection strategies for persons with
OUD and any co-occurring SUD/MH conditions, co -usage, and/or co -addiction,
including established strategies such as:
a. Self -referral strategies such as the Angel Programs or the Police Assisted Addiction
Recovery Initiative (PAARI);
b. Active outreach strategies such as the Drug Abuse Response Team (DART) model;
c. "Naloxone Plus" strategies, which work to ensure that individuals who have
received naloxone to reverse the effects of an overdose are then linked to
treatment programs or other appropriate services;
d. Officer prevention strategies, such as the Law Enforcement Assisted Diversion
(LEAD) model;
e. Officer intervention strategies such as the Leon County, Florida Adult Civil Citation
Network or the Chicago Westside Narcotics Diversion to Treatment Initiative;
f. Co -responder and/or alternative responder models to address OUD-related 911
calls with greater SUD expertise and to reduce perceived barriers associated with
law enforcement 911 responses; or
g. County prosecution diversion programs, including diversion officer salary, only for
counties with a population of 50,000 or less. Any diversion services in matters
involving opioids must include drug testing, monitoring, or treatment.
2. Support pre-trial services that connect individuals with OUD and any co-occurring
SUD/MH conditions, co -usage, and/or co -addiction to evidence -informed treatment,
including MAT, and related services.
3. Support treatment and recovery courts for persons with OUD and any co-occurring
SUD/N4H conditions, co -usage, and/or co -addiction, but only if these courts provide
referrals to evidence -informed treatment, including MAT.
4. Provide evidence -informed treatment, including MAT, recovery support, or other
appropriate services to individuals with OUD and any co-occurring SUD/W4H
conditions, co -usage, and/or co -addiction who are incarcerated in jail or prison.
5. Provide evidence -informed treatment, including MAT, recovery support or other
appropriate services to individuals with C)UD and any cm -occurring SUD/K4H
conditions, co-usage,and/or co -addiction who are leaving jail orprison have recently
left jail or prison, are on probation or parole, are under community corrections
supervision, or are in re-entry programs or facilities.
G. Support critical time interventions (CT|), particularly for individuals living with dual -
diagnosis OUD/yerious mental illness, and services for individuals who have
immediate risks and service needs and risks upon release from correctional settings.
7. Provide training on best practices for addressing the needs of criminal -justice -
involved persons with OUO and any co-occurring SUD/MH conditions, co -usage,
and/or co -addiction to |avv enforcement, correctional, or judicial personnel or to
providers of treatment, recovery, case management, or other services offered in
connection with any of the strategies described in this section.
E. ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES,
INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME
Address the needs of pregnant or parenting women with OUD and any co-occurring SUD/MH
conditions, co -usage, and/or co -addiction, and the needs oftheir families, including babies
with neonatal abstinence syndrome, through evidence -based, evidence -informed, or
promising programs or strategies that may include, but are not limited to, the following:
1. Support evdence-based,evdence-infmrnle6, orpromising treatment, including MAT,
recovery services and supports, and prevention services for pregnant women —mr
vvornenvxhocou|dbaconnepregnant—vvhmhave OUDand yany co-occurring SUD/N4H
conditions, co -usage, and/or co -addiction, and other measures to educate and
provide support tmfamilies affected byNeonatal Abstinence Syndrome.
3. Provide training for obstetricians or other healthcare personnel that work with
pregnant women and their families regarding treatment of OUD and any co-occurring
SUD/&1Hconditions, cm-usage,and/or cm -addiction.
3. provide training to health care providers who work with pregnant or parenting
women on best practices for compliance with federal requirements that children born
with Neonatal Abstinence Syndrome get referred toappropriate services and receive
aplan ofsafe care.
4. Provide enhanced support for children and family members suffering trauma as a
result of addiction in the family; and offer trauma -informed behavioral health
treatment for adverse childhood events.
5. Offer enhanced family supports and home -based wrap -around services to persons
with OUD and any co-occurring SUD/MH conditions, co -usage, and/or co -addiction,
including but not limited to parent skills training.
6. Support for Children's Services — Fund additional positions and services, including
supportive housing and other residential services, relating to children being removed
from the home and/or placed in foster care due to custodial opioid use.
PART TWO: PREVENTION
F. PREVENT OVER -PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND
DISPENSING OF OPIODS
Support efforts to prevent over -prescribing and ensure appropriate prescribing and dispensing
of opioids through evidence -based, evidence -informed, or promising programs or strategies that
may include, but are not limited to, the following:
1. Training for health care providers regarding safe and responsible opioid prescribing,
dosing, and tapering patients off opioids.
2. Academic counter -detailing to educate prescribers on appropriated opioid
prescribing.
3. Continuing Medical Education (CME) on appropriate prescribing of opioids.
4. Support for non-opioid pain treatment alternatives, including training providers to
offer or refer to multi -modal, evidence -informed treatment of pain.
5. Support enhancements or improvements to Prescription Drug Monitoring Programs
(PSMPs), including but not limited to improvements that:
A. Increase the number of prescribers using PDMPs;
B. Improve point -of -care decision -making by increasing the quantity, quality, or
format of data available to prescribers using PDMPs or by improving the
interface that prescribers use to access PDMP data, or both; or
C. Enable states to use PDMP data in support of surveillance or intervention
strategies, including MAT referrals and follow-up for individuals identified
within PDMP data as likely to experience OUD.
6. Development and implementation of a national PDMP — Fund development of a
multistate/national PDMP that permits information sharing while providing
appropriate safeguards on sharing of private health information, including but not
limited to:
a. Integration of PDMP data with electronic health records, overdose episodes,
and decision support tools for health care providers relating to OUD.
b. Ensuring PDMPs incorporate available overdose/naloxone deployment data,
including the United States Department of Transportation's Emergency
Medical Technician overdose database.
7. Increase electronic prescribing to prevent diversion or forgery.
0. Educate Dispensers mnappropriate opimiddispensing.
G. PREVENT MISUSE OF OPUOIDS
Support efforts to discourage or prevent misuse of opioids through evidence -based,
evidence -informed, or promising programs or strategies that may include, but are not limited
to, the following:
1. Corrective advertising oraffirmative public education campaigns based on evidence.
2. Public education relating tmdrug disposal.
S. Drug take -back disposal mrdestruction programs.
4. Fund community anti -drug coalitions that engage in drug prevention efforts.
5. Support community coalitions in implementing evidence -informed prevention, such
as reduced social access and physical access, stigma reduction—indudingstafUng,
educational campaigns, support for people in treatment or recovery, ortraining mf
coalitions in evidence -informed implementation, including the Strategic Prevention
Framework developed by the U.S. Substance Abuse and Mental Health Services
Administration /SAK4HSA\.
G. Engage non -profits and faith -based communities as systems to support prevention.
7. Support evidence -informed school and community education programs and
campaigns for students. Families, school employees, school athletic programs, parent -
teacher and student associations, and others.
8. School -based or youth -focused programs or strategies that have demonstrated
effectiveness in preventing drug misuse and seem likely to be effective in preventing
the uptake and use ofopioids.
9. Support community -based education or intervention services for families, youth, and
adolescents at risk for OUD and any cm -occurring SUD/W4H conditions, cm -usage,
and/or co -addiction.
10. Support evidence -informed programs or curricula to address mental health needs of
young people who may be at risk of misusing mpimids or other drugs, including
emotional modulation and resilience skills.
11.Support greater access to mental health services and supports for young people,
including services and supports provided by school nurses orother school staff, to
address mental health needs in young people that (when not properly addressed)
increase the risk mfmpioidorother drug misuse.
H. .PREVENT OVERDOSE DEATHS AND OTHER
Support efforts to prevent or reduce overdose deaths or other opioid-related harms through
evidence -based, evidence -informed, or promising programs or strategies that may include,
but are not limited to, the following:
1. Increase availability and distribution of naloxone and other drugs that treat overdoses
for first responders, overdose patients, opioid users, families and friends ofopimid
users, schools, community navigators and outreach workers, drug offenders upon
release from jail/prison, or other members of the general public.
2. Provision by public health entities of free naloxone to anyone in the community,
including but not limited to provision of intra-nasal naloxone in settings where other
options are not available or allowed.
3. Training and education regarding naloxone and other drugs that treat overdoses for
first responders, overdose patients, patients taking opioids, families, schools, and
other members of the general public.
4. Enable school nurses and other school staff to respond to opioid overdoses, and
provide them with naloxone, training, and support.
5. Expand, improve, or develop data tracking software and applications for
overdoses/naloxone revivals.
6. Public education relating to emergency responses to overdoses.
7. Public education relating to immunity and Good Samaritan laws.
8. Educate first responders regarding the existence and operation of immunity and Good
Samaritan laws.
9. Expand access to testing and treatment for infectious diseases such as HIV and
Hepatitis C resulting from intravenous opioid use.
10. Support mobile units that offer or provide referrals to treatment, recovery supports,
health care, or other appropriate services to persons that use opioids or persons with
OUD and any co-occurring SUD/MH conditions, co -usage, and/or co -addiction.
11. Provide training in treatment and recovery strategies to health care providers,
students, peer recovery coaches, recovery outreach specialists, or other professionals
that provide care to persons who use opioids or persons with OUD and any co-
occurring SUD/MH conditions, co -usage, and/or co -addiction.
12. Support Screening for fentanyl in routine clinical toxicology testing
PART THREE: OTHER STRATEGIES
I. FIRST RESPONDERS
In addition to items C8, D1 through D7, H1, H3 and H8, support the following:
1. Current and future law enforcement expenditures relating to the opioid epidemic.
2. Educate law enforcement or other first responders regarding appropriate practices
and precautions when dealing with fentanyl or other drugs.
J. LEADERSHIP, PLANNING AND COORDINATION
Support efforts to provide leadership, planning, and coordination to abate the opioid
epidemic through activities, programs, or strategies that may include, but are not limited to,
the following:
1. Community regional planning to identify goals for reducing harms related to the
opioid epidemic, to identify areas and populations with the greatest needs for
treatment intervention services, or to support other strategies to abate the opioid
epidemic described inthis opioid abatement strategy list.
3. A government dashboard to track key opioid-related indicators and supports as
identified through collaborative community processes.
3. Invest in infrastructure or staffing at government or not -for -profit agencies to support
collaborative, cross -system coordination with the purpose of preventing
overprescribing, opioid misuse, or opioid overdoses, treating those with (]UD and any
co-occurring SUD/W1Hconditions, co-usage,and/or co-addimtion,supporting them in
treatment orrecovery, connecting them tocare, mrimplementing other strategies 10
abate the opioid epidemic described inthis opioid abatement strategy list.
4. Provide resources to staff government oversight and management of opioid
abatement programs.
K. TRAINING.
In addition to the training referred to in various items abmve, support training to abate the
opioid epidemic through activities, programs, or strategies that may include, but are not
limited to, the following:
1. Provide funding for staff training ornetworking programs and services tmimprove the
capability ofgovernment, community, and not-for-proftentities toabate the opioid
crisis.
3. Invest in infrastructure and staffing for collaborative cross -system coordination to
prevent opioid misuse, prevent overdoses, and treat those with C)UD and any co-
occurring SUD/W4H conditions, co -usage, and/or co -addiction, or implement other
strategies to abate the opioid epidemic described in this opioid abatement strategy
list (e.g., health care, primary care, pharmacies, PDMPs, etc.)
L. RESEARCH
Support opioid abatement research that may include, but is not limited to, the following:
1. Monitoring, surveillance, and evaluation of programs and strategies described in this
2. Research non-opioid treatment of chronic pain.
3. Research onimproved service delivery for modalities such asS8|NTthat demonstrate
promising but mixed results in populations vulnerable boopioid use disorders.
4. Research on innovative supply-side enforcement efforts such msimproved detection
of mail -based delivery ofsynthetic opioids.
5. Expanded research on swift/certain/fair models to reduce and deteropimid misuse
within criminal justice populations that build upon promising approaches used to
address other substances (e.g. Hawaii HOPE and Dakota 24/7).
6. Research on expanded modalities such as prescription methadone that can expand
access toMAT.
1
ITEM TITLE:
BUSINESS OF THE CITY COUNCIL
YAKIMA, WASHINGTON
AGENDA STATEM ENT
Item No. 11.
For Meeting of: June 6, 2023
Resolution authorizing the Memorandum of Understanding between
the Greater Columbia Region municipalities to establish an opioid
abatement council
SUBMITTED BY: Sara Watkins, City Attorney
SUMMARY EXPLANATION:
The City has joined with other municipalities to settle multiple opioid-related lawsuits against
manufacturers and pharmacies. As a condition to spending settlement funds, participating
jurisdictions must establish regional opioid abatement councils. This MOU establishes the
Greater Columbia Region opioid abatement council, which will have general oversight over the
use of the funds to ensure participating jurisdictions are using settlement proceeds according to
the terms of the allocation agreements. It also will serve as a review board if there are disputes
over the proper use of the funds.
ITEM BUDGETED: No
STRATEGIC PRIORITY: Public Safety
APPROVED FOR SUBMITTAL BY THE CITY MANAGER
RECOMMENDATION:
Adopt resolution.
ATTACHMENTS:
Description Upload Date
0 Res-Opioid_Settlement_Opioid Abatement Council 5/15/2023
❑ MOU Opioid Abatement Council 5/26/2023
Type
Resolution
Corer Memo